

itu

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number  
**WO 01/64221 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/52**

Windsor, NJ 08550 (US). FAKES, Michael, G. [US/US]:  
15 Derby Chase Court, Belle Mead, NJ 08502 (US).

(21) International Application Number: **PCT/US01/02630**

(74) Agents: **ALGIERI, Aldo, A. et al.**: Bristol-Myers Squibb  
Co., P.O. Box 4000, Lawrenceville-Princeton Rd., Prince-  
ton, NJ 08543 (US).

(22) International Filing Date: 26 January 2001 (26.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/185,672 29 February 2000 (29.02.2000) US  
60/221,313 28 July 2000 (28.07.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): **BRIS-  
TOL-MYERS SQUIBB CO.** [US/US]; P.O. Box 4000,  
Lawrenceville-Princeton Rd., Princeton, NJ 08543 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **COLONNO,**  
Richard, J. [US/US]; 18 Salisbury Way, Farmington,  
CT 06032 (US). **SPROCKEL, Omar, L.** [US/US]; 1250  
Dogwood Drive, Bridgewater, NJ 08807 (US). **HARI-  
ANAWALA, Abizer** [IN/US]; Apt. #A, 607 Cranbury  
Cross Rd., North Brunswick, NJ 8902 (US). **DESAI,**  
Divyakant [IN/US]; 19 Greenfield Drive North, West

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



**WO 01/64221 A1**


(54) Title: **LOW DOSE ENTECAVIR FORMULATION AND USE**

(57) Abstract: Compositions containing a low dose of entecavir are administered on a daily basis to treat hepatitis B virus infection and/or co-infections. Formulations for the oral administration of a low dose of entecavir are provided. Other pharmaceutically active substances can be included in the entecavir composition or can be separately administered for the treatment of hepatitis B virus infection or for the treatment of co-infected patients.

Low Dose Entecavir Formulation And Use

5

Entecavir, [1S-(1 $\alpha$ ,3 $\alpha$ ,4 $\beta$ )]-2-amino-1,9-dihydro-9-[4-  
10 hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-  
purin-6-one



is an antiviral agent currently undergoing clinical  
15 evaluation for the treatment of hepatitis B virus  
infection.

Entecavir and its use in treating hepatitis B are  
disclosed by Zahler et al. in U.S. Patent 5,206,244.  
This patent discloses that an effective antiviral dose  
20 for oral or parenteral administration will likely be in  
the range of about 1.0 to 50 mg/kg of body weight and  
that the desired dose may be administered several times  
daily at appropriate intervals.

Improved methods for the synthesis of entecavir are  
25 disclosed by Bisacchi et al. in WO 98/09964.

This invention is directed to pharmaceutical compositions containing a low dose of entecavir and the use of such low dose composition to safely and effectively treat hepatitis B virus infection.

This invention is also directed to pharmaceutical compositions for oral administration containing low doses of a pharmaceutically active substance. This result is achieved by adhering particles of the pharmaceutically active substance to the surface of a carrier substrate. The process of depositing the active substance on the carrier substrate is controlled to minimize the agglomeration of the active substance/carrier substrate particles.

15

This invention is directed to pharmaceutical compositions containing a low dose of from about 0.001 mg to about 25 mg of the active antiviral agent entecavir for once daily administration to treat hepatitis B virus infection in an adult human patient. Preferred pharmaceutical compositions contain from about 0.01 mg to about 10 mg of entecavir and most preferred pharmaceutical compositions contain from about 0.01 to about 5 mg of entecavir. Such preferred and most preferred pharmaceutical compositions are also administered once daily to treat hepatitis B virus infection in an adult patient.

The term adult human patient is defined as a patient of about 16 years or more of age and a weight equal to or greater than about 50 kilograms. Pharmaceutical compositions containing entecavir at the lower end of the above ranges are suitable for administration to pediatric

30

patients or adult patients weighing less than about 50 kilograms.

The low dose entecavir pharmaceutical compositions described above for daily administration may also be administered to certain patients less often. For example, patients who have been treated by daily administration of the low dose entecavir pharmaceutical compositions so that their hepatitis B virus infection is now under control may be placed on a maintenance regimen to protect against further infection. Such maintenance therapy may involve the administration of the low dose entecavir composition on a less than daily basis. For example, a single dose administered every three or four days or administered on a weekly basis may be sufficient.

The low dose entecavir pharmaceutical compositions of this invention can be formulated for administration by any suitable means. For example, compositions for oral administration, which are preferred, can be in the form of tablets, capsules, granules or powders or in the form of elixirs, solutions or suspensions. The low dose entecavir pharmaceutical compositions may also be formulated for parenteral, rectal, transdermal or nasal administration according to methods well known in the art. Such formulations can include pharmaceutically acceptable excipients including bulking agents, lubricants, disintegrants, binding agents, etc. as commonly employed in such compositions. Sustained release formulations are also within the scope of this invention.

Surprisingly, it has been found that once daily administration of the low dose entecavir pharmaceutical compositions of this invention are effective in treating hepatitis B virus infection without undesirable side effects that can result from administration of the high dose regimen described in U.S. Patent 5,206,244.

This invention is also directed to the treatment of hepatitis B virus infection with low dose entecavir compositions as described above in combination with one or more other pharmaceutically active agents. Suitable pharmaceutically active agents for this purpose include one or more antiviral agents, for example, didanosine, lamivudine, abacavir, adefovir, adefovir dipivoxil, famciclovir, (2R,4R)-4-(2,6-diamino-9H-purin-9-yl)-2-hydroxymethyl-1,3-dioxolane (DAPD), hepatitis B immunomodulating proteins (EHT 899 from Enzo Biochem), emtricitabine, 1-(2-deoxy-2-fluoro- $\beta$ -D-arabinofuranosyl)thymine (FMAU), GLQ-223 (Compound A,  $\alpha$ -trichosanthin), epavudine (L-dT), epcitabine (L-dC), ribavirin, tenofovir (PMPA), 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine[L(-)Fd4C], as well as other fluoro L- and D- nucleosides. Suitable pharmaceutically active agents for this purpose also include one or more immunomodulators, for example,  $\alpha$  interferon,  $\beta$  interferon, pegylated interferon, thymosin  $\alpha$ , and hepatitis B vaccines such as HBV/MF59, Hepagene and Theradigm-HBV.

When the other pharmaceutically active agent or agents are suitable for oral administration, they can be combined with the low dose of entecavir into a single tablet or capsule. If the other pharmaceutically active agent or agents are not compatible with entecavir for co-administration from a single dosage form, for example, if the mode of administration is different or if the frequency of administration is different, then the other pharmaceutically active agent or agents will be administered separately. The amount of the other agent or agents administered is that conventionally employed in mono therapy or a reduced amount as determined by the treating physician. The separate dose forms can be

administered at the same time or sequentially according to a prescribed schedule.

This invention also includes the treatment of co-infected patients with the low dose entecavir compositions described above. A co-infected patient is one infected with other viral or non-viral diseases in addition to hepatitis B. In particular, such treatment is possible for hepatitis B patients co-infected with hepatitis C or HIV. Such co-infected patients are preferably treated with the low dose entecavir compositions as described above in combination with one or more other pharmaceutically active agents as described above. For example, a patient co-infected with hepatitis B and hepatitis C can be treated with the low dose entecavir composition in addition to being treated with a regimen of ribavirin and an interferon.

Another aspect of this invention is the preparation of pharmaceutical compositions, particularly tablets and capsules, containing entecavir in an amount of less than or equal to about 10 mg. Such compositions cannot be prepared with good content uniformity by simply mixing the active substance and the excipients. The traditional methods of granulation are also not suitable for products active at such low doses.

Tablet and capsule formulations containing from about 0.001 mg to about 10 mg of entecavir are prepared according to the following procedures that ensure high potency and good uniformity of the product. The compositions are prepared by first carefully depositing the entecavir on the surface of carrier substrate particles. This step is accomplished by forming a solution of the entecavir in a solvent along with an adhesive substance at temperatures ranging from about 25°C to about 80°C and applying the solution as a spray or a stream while the carrier substrate particles are in

motion. The conditions are controlled to minimize particle agglomeration. Subsequently, the solvent is removed from the carrier surface leaving the entecavir particles adhered to the surface of the carrier substrate. This prevents the separation of the entecavir from the substrate and minimizes the loss of entecavir during subsequent processing.

Following drying, the entecavir coated carrier substrate particles are mixed with any other ingredients to be included in the composition such as a disintegrant and/or lubricant. The resulting powder is then compressed into tablets or filled into capsules.

The carrier substrate particles are kept in motion during the spraying step by means of mechanical or air stream agitation. In the mechanical agitation procedure, the carrier substrate is placed in a mechanical (high shear) mixer and agitated. A solution containing the entecavir and adhesive substance maintained at a temperature of from about 25°C to about 80°C is sprayed onto the carrier substrate particles at a controlled rate and atomizing pressure (0 to 2 bar). To maximize the amount of entecavir deposited on the carrier, the position of the spray assembly is adjusted to make certain that the spray pattern only encompasses the carrier. The rate of deposition and the spray pattern are controlled to minimize particle agglomeration. Once the entecavir containing solution is deposited, the wet entecavir/carrier substrate particles are transferred to a drier, either a tray drier or fluidbed drier is suitable. The solvent is removed at an elevated temperature. When the solvent is water or pH adjusted water, a temperature of from about 50° to about 80°C is suitable.

In the air stream agitation procedure, the carrier substrate is placed in a bowl with a fine mesh screen at the bottom. The incoming air stream is adjusted so that the substrate particle motion is constant and fluid. The carrier material is equilibrated to a temperature of from about 25°C to about 80°C. A solution containing the entecavir and adhesive substance maintained at a temperature of from about 25°C to about 80°C is sprayed onto the carrier substrate particles at a controlled rate and atomizing pressure as described above. Again, the position of the spray assembly is adjusted to make certain that the spray pattern only encompasses the carrier and the rate of deposition is controlled to minimize particle agglomeration. Once the entecavir solution is deposited, the temperature is elevated to remove the solvent. When the solvent is water or pH adjusted water, a temperature of from about 50°C to about 80°C is suitable. In the air stream agitation procedure, both the deposition of the entecavir onto the carrier substrate and the removal of the solvent are carried out in a single unit whereas the mechanical agitation procedure requires a two-unit operation.

The above procedures have the additional advantage of reducing exposure of the manufacturing personnel to entecavir in the atmosphere of the facility.

While the above procedures are described for preparing pharmaceutical compositions containing from about 0.005 mg to about 10 mg of entecavir, they can also be employed to prepare pharmaceutical compositions containing low doses of any soluble pharmaceutically active substance.

Preferred solvents in the above procedures are water and pH adjusted water. The solubility of entecavir in water can be increased by lowering the pH of water by the



addition of an acid such as hydrochloric acid or by raising the pH of water by the addition of a base such as ammonium hydroxide.

The adhesive substance is preferably a polymeric material possessing a high degree of tackiness. Suitable materials include povidone, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, guar gum, and xanthan gum and mixtures thereof with povidone being preferred. The adhesive substance is preferably present in the final composition at from about 0.01% to about 10% by weight of the total composition.

The carrier substrate is a pharmaceutically acceptable substance that can be readily spray coated and yet will not easily agglomerate. Suitable materials include lactose, microcrystalline cellulose, calcium phosphate, dextrin, dextrose, dextrates, mannitol, sorbitol, and sucrose and mixtures thereof with lactose and microcrystalline cellulose and mixtures thereof being preferred. The carrier substrate is preferably present in the final composition at from about 80% to about 95% by weight of the total composition.

A disintegrant is preferably included in the final composition at from about 1% to about 7% by weight of the total composition. Suitable disintegrants include crospovidone, croscarmellose, sodium starch glycolate, pregelatinized starch, and corn starch and mixtures thereof with crospovidone being preferred.

A lubricant is preferably included in the final composition at from about 0.1% to about 5% by weight of the total composition. Suitable lubricants include magnesium stearate, stearic acid, sodium stearyl fumarate, and sodium lauryl sulfate with magnesium stearate being preferred.

The resulting tablet or capsule can be film coated for ease of administration. Suitable materials for use in the film coating are polymeric coating agents, pigments, plasticizers, solubilizing agents, etc.

- 5 Suitable coating agents include hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate, etc. Polyethylene glycol can be included in the film coating composition as a plasticizer. Additional plasticizers  
10 such as diethyl citrate and triethyl citrate may also be included in the film coating composition. Suitable solubilizing agents include polyoxyethylene sorbitan fatty acid esters particularly polysorbate 80. Suitable pigments include titanium dioxide and various iron  
15 oxides.

- The ingredients of the coating compositions are dispersed in a suitable solvent, preferably water. The coating composition can be applied to the tablets or capsules using conventional pan coating or spray coating  
20 techniques.

The following examples describe low dose entecavir compositions within the scope of this invention.

Example 1

Employing the above procedures a tablet of 0.5 milligram strength entecavir was prepared.

5

Ingredient	Amount % weight/weight	Amount per tablet
Entecavir	0.5	0.50 mg
Lactose monohydrate, NF	60.00	60.00 mg
Microcrystalline cellulose, NF	32.50	32.50 mg
Crospovidone, NF	4.00	4.00 mg
Povidone, USP	2.50	2.50 mg
Magnesium Stearate, NF	0.50	0.50 mg
Purified Water, USP*	q.s.	---
Total	100.00	100.00 mg

\*removed by drying

Example 2

Employing the above procedures a tablet of 0.1 milligram strength entecavir was prepared.

5

Ingredient	Amount % weight/weight	Amount per capsule
Entecavir	0.1	0.1 mg
Lactose monohydrate, NF	60.00	60.00
Microcrystalline cellulose, NF	35.39	35.39 mg
Crospovidone, NF	4.0	4.00 mg
Povidone, USP	0.01	0.01 mg
Magnesium Stearate, NF	0.5	0.5 mg
Purified Water, USP*	q.s.	---
Total	100.00	100.00 mg

\*removed by drying

Example 3

Employing the above procedures a tablet of 0.01 milligram strength entecavir was prepared.

5

Ingredient	Amount % weight/weight	Amount per tablet
Entecavir	0.01	0.01 mg
Microcrystalline cellulose, NF	93.24	93.24 mg
Crospovidone, NF	4.00	4.00 mg
Povidone, USP	2.50	2.50 mg
Magnesium Stearate, NF	0.25	0.25 mg
Purified Water, USP*	q.s.	---
Total	100.00	100.00 mg

\*removed by drying

Example 4

Employing the above procedures a 10 milligram strength entecavir capsule was prepared.

5

Ingredient	Amount % weight/weight	Amount per capsule
Entecavir	10.00	10.00 mg
Microcrystalline cellulose, NF	82.03	82.03 mg
Crospovidone, NF	4.00	4.00 mg
Povidone, USP	2.50	2.50 mg
Magnesium Stearate, NF	0.25	0.25 mg
Hydrochloric acid	1.22	1.22 mg
Purified Water, USP*	q.s.	---
Total	100.00	100.00 mg

Capsule shell

----

\*removed by drying

Example 5

Employing the above procedures a 0.05 milligram strength entecavir capsule was prepared.

5

Ingredient	Amount % weight/weight	Amount per capsule
Entecavir	0.05	0.05 mg
Dicalcium phosphate, NF	93.20	93.20 mg
Crospovidone, NF	4.00	4.00 mg
Hydroxypropyl cellulose, NF	2.50	2.50 mg
Magnesium Stearate, NF	0.25	0.25 mg
Purified Water, USP*	q.s.	---
Total	100.00	100.00 mg
Capsule shell	----	

\*removed by drying

Example 6

Employing the above procedures a tablet of 1 milligram strength entecavir was prepared.

5

Ingredient	Amount % weight/weight	Amount per tablet
Entecavir	1.00	1.00 mg
Mannitol, NF	90.00	90.00 mg
Croscarmellose sodium, NF	4.00	4.00 mg
Methyl Cellulose, NF	2.50	2.50 mg
Stearic Acid, NF	2.50	0.25 mg
Purified Water, USP*	q.s.	---
Total	100.00	100.00 mg

\*removed by drying



Example 7

The 100 mg tablet of Example 1 containing 0.5 mg of entecavir, the 100 mg tablet of Example 2 containing 0.1 mg of entecavir, the 100 mg tablet of Example 3 containing 0.01 mg of entecavir and the 100 mg tablet of Example 6 containing 1.0 mg of entecavir can be film coated with the composition set forth below using conventional pan coating or spray coating techniques.

10

Ingredient	Amount	Amount
	% weight/weight	per tablet <sup>1</sup>
Opadry®	1 to 10	1 to 10 mg
Plasticizer <sup>*</sup>	0 to 10	0 to 10 mg
Purified Water, USP <sup>*</sup>	q.s.	----

<sup>\*</sup>removed by drying

Opadry® is commercially available and contains hydroxypropylmethylcellulose, titanium dioxide, polyethylene glycol, polysorbate 80, synthetic yellow iron oxide and synthetic red iron oxide.

<sup>1</sup> The calculations are done assuming a tablet weight of 100 mg.

<sup>2</sup> Suitable plasticizers are diethyl citrate and triethyl citrate.

Example 8

The safety and antiviral activity of entecavir given for 28 days to human subjects with chronic hepatitis B virus infection was studied in a randomized, double-blind, placebo-controlled, dose-escalating trial. Entecavir demonstrated potent antiviral activity at all doses tested. The mean log reduction in hepatitis B virus DNA viral levels in the blood at day 28 were 2.21, 2.25, 2.81, and 2.42 for the 0.05, 0.1, 0.5 and 1.0 mg once daily doses of entecavir, respectively. Entecavir was well tolerated.

Example 9

The safety and antiviral activity of three doses of entecavir (0.01 mg, 0.1 mg and 0.5 mg) given once daily for 24 weeks were studied in adults with chronic hepatitis B in a randomized, double-blind, lamivudine (100 mg QD) controlled trial. All three doses of entecavir demonstrated potent antiviral activity. The two higher doses of entecavir produced significantly greater reductions in hepatitis B virus DNA viral levels in blood compared to lamivudine. Entecavir at all doses was well tolerated.

What is claimed is:

1. A pharmaceutical composition for once a day administration to treat hepatitis B virus infection comprising a pharmaceutically acceptable carrier and from about 0.001 mg to about 25 mg of entecavir.
2. A composition of Claim 1 wherein: said entecavir is present at from about 0.01 mg to about 10 mg.
3. A composition of Claim 1 wherein: said entecavir is present at from about 0.01 mg to about 5 mg.
4. A composition of Claim 3 wherein said entecavir is present at about 0.01 mg.
5. A composition of Claim 3 wherein said entecavir is present at about 0.05 mg.
6. A composition of Claim 3 wherein said entecavir is present at about 0.1 mg.
7. A composition of Claim 3 wherein said entecavir is present at about 0.5 mg.
8. A composition of Claim 3 wherein said entecavir is present at about 1.0 mg.
9. A composition of Claim 1 in the form of a tablet or capsule.
10. A composition of Claim 1 containing one or more other pharmaceutically active substances.

11. A pharmaceutical composition for oral  
administration of a low dose of entecavir comprising:  
from about 0.001 mg to about 10 mg of entecavir  
5 adhered to a carrier substrate.

12. A composition of Claim 11 wherein:  
said carrier substrate is selected from lactose,  
microcrystalline cellulose, calcium phosphate, dextrin,  
10 dextrose, dextrates, mannitol, sorbitol and sucrose, and  
mixture thereof, and  
said entecavir is adhered to said substrate by an  
adhesive substance which is a polymeric material  
possessing sufficient tack.

15 13. A composition of Claim 12 wherein:  
said adhesive substance is selected from povidone,  
methylcellulose, hydroxymethylcellulose, hydroxypropyl-  
methylcellulose, hydroxypropylcellulose, hydroxyethyl-  
20 cellulose, gelatin, guar gum, and xanthan gum and  
mixtures thereof.

14. A composition of Claim 11 including a lubricant  
and a disintegrant wherein:  
25 said lubricant is selected from magnesium stearate,  
stearic acid, sodium stearyl fumarate, and sodium lauryl  
sulfate, and mixtures thereof and said disintegrant is  
selected from crospovidone, croscarmellose sodium, sodium  
starch glycolate, pregelatinized starch, and corn starch  
30 and mixtures thereof.

15. A pharmaceutical composition for oral administration of a low dose of entecavir comprising entecavir coated by means of an adhesive substance to a carrier substrate, a lubricant, and a disintegrant  
5 wherein:

said entecavir is present at from about 0.001 to about 10% by weight of said composition,

said adhesive substance is present at from about 0.01 to about 10% by weight of said composition,

10 said carrier substrate is present at from about 80 to about 95% by weight of said composition,

said disintegrant is present at from about 1 to about 7% by weight of said composition, and

said lubricant is present at from about 0.1 to about  
15 5% by weight of said composition.

16. A composition of Claim 15 wherein:

said adhesive substance is selected from povidone, methylcellulose, hydroxymethylcellulose, hydroxypropyl-  
20 methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, gelatin, guar gum, and xanthan gum and mixtures thereof,

said carrier substrate is selected from lactose, microcrystalline cellulose, calcium phosphate, dextrin,  
25 dextrose, dextrans, mannitol, sorbitol, and sucrose and mixtures thereof,

said disintegrant is selected from crospovidone, croscarmellose sodium, sodium starch glycolate, pregelatinized starch, and corn starch, and mixtures  
30 thereof, and

said lubricant is selected from magnesium stearate, stearic acid, sodium stearyl fumarate, and sodium lauryl sulfate, and mixtures thereof.

17. A composition of Claim 16 wherein:  
said adhesive substance is povidone; said carrier  
substrate is microcrystalline cellulose or lactose or  
mixtures thereof; said disintegrant is crospovidone; and  
5 said lubricant is magnesium stearate.

18. The low dose entecavir tablet composition  
comprising:  
about 0.01% entecavir,  
10 about 93.24% microcrystalline cellulose,  
about 4.0% crospovidone,  
about 2.50% povidone, and  
about 0.25% magnesium stearate, said percentages  
being on a weight/weight basis; or  
15 about 1.0% entecavir,  
about 90.0% mannitol,  
about 4.0% croscarmellose sodium,  
about 2.50% methyl cellulose, and  
about 2.50% stearic acid, said percentages being on  
20 a weight/weight basis; or  
about 0.5% entecavir,  
about 60.00% lactose monohydrate,  
about 32.50% microcrystalline cellulose,  
about 4.0% crospovidone,  
25 about 2.50% povidone, and  
about 0.50% magnesium stearate, said percentages  
being on a weight/weight basis; or  
about 0.1% entecavir,  
about 60.00% lactose monohydrate,  
30 about 35.39% microcrystalline cellulose,  
about 4.0% crospovidone,  
about 0.01% povidone, and  
about 0.5% magnesium stearate, said percentage being  
on a weight/weight basis.

35

19. The low dose entecavir tablet composition of Claim 18 having an outer film coating.

20. The low dose entecavir capsule composition  
5 comprising:  
about 10.0% entecavir,  
about 82.03% microcrystalline cellulose,  
about 4.00% crospovidone,  
about 2.50% povidone,  
10 about 0.25% magnesium stearate, and  
about 1.22% hydrochloric acid, said percentages being on  
a weight/weight basis; or  
about 0.05% entecavir,  
about 93.20% dicalcium phosphate,  
15 about 4.00% crospovidone,  
about 2.50% hydroxypropyl cellulose, and  
about 0.25% magnesium stearate, said percentages  
being on a weight/weight basis.

20 21. The method of preparing a pharmaceutical  
composition for oral administration containing a low dose  
of a soluble pharmaceutically active agent comprising:  
(a) dissolving said pharmaceutically active agent  
and an adhesive substance in a solvent,  
25 (b) spraying said solution from step (a) onto a  
carrier substrate while said carrier substrate is in  
motion,  
(c) drying said coated carrier substrate from step  
(b) to remove said solvent, and  
30 (d) combining said dried coated carrier substrate  
from step (c) with other desired ingredients to form said  
pharmaceutical composition.

22. The method of Claim 21 wherein:  
said pharmaceutically active substance is entecavir which  
is present at from about 0.001 to about 10% on a  
weight/weight basis of said composition, and said solvent  
5 is water or water having an acidic or basic pH.

23. The method of Claim 21 wherein:  
said carrier substrate is kept in motion during spraying  
step (b) by mechanical agitation, and  
10 said coated carrier substrate is dried in step (c) in a  
tray drier or fluidbed drier; or said carrier substrate  
is kept in motion during spraying step (b) by air stream  
agitation, and  
said coated carrier substrate is dried in step (c) also  
15 by means of air stream agitation.



# INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 01/02630

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, CHEM ABS Data, EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, SCISEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GRAUL, A. ET AL: "BMS - 200475: Anti-HBV" DRUGS FUTURE (1999), 24(11), 1173-1177 , XP000995923 page 1176	1-3,8, 10,11
X	GENOVESI E V ET AL: "Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS - 200475 in the woodchuck model of hepatitis B virus infection 'published erratum appears in Antimicrob Agents Chemother 1999 Mar;43(3):726!." ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1998 DEC) 42 (12) 3209-17. , XP000996177 abstract	1-3,8, 10,11
Y	page 3210 -page 3216 -/-	1-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*S\* document member of the same patent family

Date of the actual completion of the international search

26 April 2001

Date of mailing of the international search report

17/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Brunnauer, H

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/02630

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 481 754 A (SQUIBB & SONS INC) 22 April 1992 (1992-04-22) page 3, line 55 -page 4, line 10 page 5, line 50 -page 6, line 2 page 34, line 25-30 claim 15	1-23
Y	DE CLERCQ E: "Perspectives for the treatment of hepatitis B virus infections." INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, (1999 JUL) 12 (2) 81-95. REF: 72 , XP000901672 page 86; table 1 page 93, left-hand column	1-23
Y	BISACCHI, G. S. ET AL: "BMS - 200475, a novel carbocyclic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro" BIOORG. MED. CHEM. LETT. (1997), 7(2), 127-132 , XP004135980 page 131	1-23
Y	US 4 631 284 A (SALPEKAR ANIL M ET AL) 23 December 1986 (1986-12-23) column 1, line 1-16 column 6, line 52-59 column 7, line 2-37 claim 1	1-23

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int lional Application No

PCT/US 01/02630

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0481754 A	22-04-1992	AT 157095 T	15-09-1997
		AU 634423 B	18-02-1993
		AU 8559891 A	30-04-1992
		BR 1100846 A	18-04-2000
		CA 2053339 A	19-04-1992
		CN 1061972 A,B	17-06-1992
		CY 2063 A	12-06-1998
		DE 69127336 D	25-09-1997
		DK 481754 T	15-09-1997
		ES 2104673 T	16-10-1997
		FI 914928 A	19-04-1992
		GR 3025395 T	27-02-1998
		HK 1001343 A	12-06-1998
		HU 213207 B	28-03-1997
		IE 913451 A	22-04-1992
		IL 99755 A	04-08-1996
		JP 2994117 B	27-12-1999
		JP 4282373 A	07-10-1992
		KR 160523 B	01-12-1998
		NO 179906 B	30-09-1996
		NZ 240053 A	26-05-1993
		PL 169403 B	31-07-1996
		PT 99281 A,B	31-08-1992
		SG 70958 A	21-03-2000
		RU 2037496 C	19-06-1995
		US 5340816 A	23-08-1994
		US 5206244 A	27-04-1993
		ZA 9107894 A	31-03-1993
US 4631284 A	23-12-1986	NONE	